Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CARA Cara Therapeutics		$15.19	$8.13 ▼ $19.08	$24.33M	0.41	22,209 shs	237,144 shs
MNKD MannKind	$3.77 -0.8%	$4.10	$3.51 ▼ $7.63	$1.15B	0.96	2.44 million shs	1.82 million shs
PAHC Phibro Animal Health	$30.80 -1.1%	$24.79	$16.16 ▼ $31.80	$1.25B	0.75	221,135 shs	330,261 shs
VERU Veru	$0.60 +3.0%	$0.57	$0.45 ▼ $1.42	$88.02M	-0.75	1.93 million shs	1.56 million shs
ZIOP ZIOPHARM Oncology		$1.08	$0.77 ▼ $5.95	$187.12M	1.71	2.01 million shs	2.13 million shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CARA Cara Therapeutics	0.00%	0.00%	0.00%	+8.57%	+55.01%
MNKD MannKind	-0.79%	+4.58%	-2.84%	-19.10%	-31.83%
PAHC Phibro Animal Health	-1.09%	+10.04%	+26.28%	+76.00%	+87.92%
VERU Veru	+2.97%	+0.08%	-10.71%	+10.65%	-31.84%
ZIOP ZIOPHARM Oncology	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CARA Cara Therapeutics	0.3021 of 5 stars	0.0	0.0	0.0	4.2	0.6	0.8	0.0
MNKD MannKind	2.4278 of 5 stars	3.6	0.0	0.0	0.0	1.6	1.7	1.9
PAHC Phibro Animal Health	4.0532 of 5 stars	0.9	4.0	2.5	1.1	3.1	3.3	2.5
VERU Veru	2.9016 of 5 stars	3.5	4.0	0.0	0.0	3.3	1.7	0.0
ZIOP ZIOPHARM Oncology	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CARA Cara Therapeutics	0.00	N/A	N/A	N/A
MNKD MannKind	3.29	Buy	$10.33	174.09% Upside
PAHC Phibro Animal Health	1.83	Reduce	$24.40	-20.78% Downside
VERU Veru	3.00	Buy	$4.00	566.11% Upside
ZIOP ZIOPHARM Oncology	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest CARA, MNKD, PAHC, VERU, and ZIOP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/7/2025	PAHC Phibro Animal Health	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$25.00 ➝ $35.00
6/25/2025	PAHC Phibro Animal Health	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Equal Weight ➝ Equal Weight	$21.00 ➝ $26.00
6/16/2025	PAHC Phibro Animal Health	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
6/16/2025	PAHC Phibro Animal Health	BNP Paribas Exane Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underperform ➝ Neutral	$24.00
5/8/2025	PAHC Phibro Animal Health	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$20.00 ➝ $21.00
4/15/2025	PAHC Phibro Animal Health	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$20.00

(Data available from 7/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CARA Cara Therapeutics	$7.14M	0.00	N/A	N/A	$12.58 per share	0.00
MNKD MannKind	$285.50M	4.01	$0.14 per share	27.17	($0.29) per share	-13.00
PAHC Phibro Animal Health	$1.02B	1.23	$2.11 per share	14.57	$6.34 per share	4.86
VERU Veru	$16.89M	5.21	N/A	N/A	$0.22 per share	2.73
ZIOP ZIOPHARM Oncology	N/A	N/A	N/A	N/A	$0.58 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CARA Cara Therapeutics	-$118.51M	-$21.01	N/A	N/A	N/A	-1,099.76%	-367.97%	-107.43%	N/A
MNKD MannKind	$27.59M	$0.10	37.70	16.39	N/A	10.12%	-32.41%	10.85%	8/6/2025 (Estimated)
PAHC Phibro Animal Health	$2.42M	$0.78	39.49	14.67	0.52	2.68%	30.51%	6.89%	8/27/2025 (Estimated)
VERU Veru	-$37.80M	-$0.24	N/A	N/A	N/A	N/A	-128.51%	-76.51%	8/6/2025 (Estimated)
ZIOP ZIOPHARM Oncology	-$79.98M	-$0.43	N/A	N/A	N/A	N/A	-92.84%	-72.46%	N/A

Latest CARA, MNKD, PAHC, VERU, and ZIOP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2025	Q2 2025	MNKD MannKind	$0.04	N/A	N/A	N/A	$77.82 million	N/A
5/8/2025	Q1 2025	MNKD MannKind	$0.03	$0.04	+$0.01	$0.04	$75.86 million	$78.35 million
5/8/2025	Q2 2025	VERU Veru	-$0.06	-$0.05	+$0.01	-$0.05	$0.73 million	N/A
5/7/2025	Q3 2025	PAHC Phibro Animal Health	$0.52	$0.63	+$0.11	$0.51	$352.41 million	$347.80 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CARA Cara Therapeutics	N/A	N/A	N/A	N/A	N/A
MNKD MannKind	N/A	N/A	N/A	N/A	N/A
PAHC Phibro Animal Health	$0.48	1.56%	N/A	61.54%	N/A
VERU Veru	N/A	N/A	N/A	N/A	N/A
ZIOP ZIOPHARM Oncology	N/A	N/A	N/A	N/A	N/A

Latest CARA, MNKD, PAHC, VERU, and ZIOP Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/6/2025	PAHC Phibro Animal Health	quarterly	$0.12	2.52%	6/4/2025	6/4/2025	6/25/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CARA Cara Therapeutics	N/A	4.77	4.71
MNKD MannKind	N/A	2.36	2.11
PAHC Phibro Animal Health	2.67	2.91	1.23
VERU Veru	N/A	3.80	3.80
ZIOP ZIOPHARM Oncology	0.18	3.43	3.43

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CARA Cara Therapeutics	44.66%
MNKD MannKind	49.55%
PAHC Phibro Animal Health	99.34%
VERU Veru	47.16%
ZIOP ZIOPHARM Oncology	51.03%

Insider Ownership

Company	Insider Ownership
CARA Cara Therapeutics	3.10%
MNKD MannKind	2.70%
PAHC Phibro Animal Health	50.07%
VERU Veru	15.20%
ZIOP ZIOPHARM Oncology	5.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CARA Cara Therapeutics	80	4.57 million	4.43 million	Optionable
MNKD MannKind	400	303.93 million	295.73 million	Optionable
PAHC Phibro Animal Health	1,940	40.53 million	20.24 million	Optionable
VERU Veru	230	146.58 million	124.30 million	Optionable
ZIOP ZIOPHARM Oncology	105	216.15 million	204.91 million	Optionable

CARA, MNKD, PAHC, VERU, and ZIOP Headlines

Recent News About These Companies

TCRT stock touches 52-week low at $1.62 amid market challenges

January 30, 2025 | msn.com

Best Global Universities for Oncology

September 11, 2024 | usnews.com

FDA fast-tracks Merck's cancer blockbuster-in-waiting

July 28, 2024 | pharmaphorum.comP

BMS signs $475m cancer immunotherapy deal with Dragonfly

July 23, 2024 | pharmaphorum.comP

Childhood Cancers

February 17, 2024 | curetoday.comC

Alx Oncology Holdings (ALXO)

February 10, 2024 | investing.com

Pediatric Hematology-Oncology Fellowship

February 5, 2024 | bcm.eduB

Alaunos Therapeutics: Other Events, Financial Statements And Exhibits

January 31, 2024 | cbonds.comC

CG Oncology Inc

January 31, 2024 | reuters.com

Oncology Nurses' Narratives About Ethical Dilemmas and Prognosis-Related Communication in Advanced Cancer Patients

December 21, 2023 | medscape.comM

Immuno-Oncology

December 19, 2023 | ajmc.comA

Why Is Alaunos Therapeutics (TCRT) Stock Up 37% Today?

December 18, 2023 | markets.businessinsider.com

Exploring Patient-Centered Handoffs in Surgical Oncology

December 10, 2023 | medscape.comM

Association of Community Cancer Centers

October 14, 2023 | ajmc.comA

Oncology News and Research

September 19, 2023 | news-medical.netN

WBSPH 2024 - Oncology

September 15, 2023 | newsweek.comN

Kris on Oncology

September 6, 2023 | medscape.comM

Gauging Ziopharm's Chances for Positive Sarcoma Drug Trial Results

August 29, 2023 | thestreet.com

Oncology Cases & Quizzes

August 14, 2023 | medscape.comM

Ziopharm’s palifosfamide fails in first-line STS…

June 20, 2023 | investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CARA, MNKD, PAHC, VERU, and ZIOP Company Descriptions

Cara Therapeutics NASDAQ:CARA

Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

MannKind NASDAQ:MNKD

$3.77 -0.03 (-0.79%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$3.78 +0.01 (+0.16%)

As of 07/11/2025 07:56 PM Eastern

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

Phibro Animal Health NASDAQ:PAHC

$30.80 -0.34 (-1.09%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$30.78 -0.03 (-0.08%)

As of 07/11/2025 05:25 PM Eastern

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.

Veru NASDAQ:VERU

$0.60 +0.02 (+2.97%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$0.59 -0.01 (-1.75%)

As of 07/11/2025 07:55 PM Eastern

Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.

ZIOPHARM Oncology NASDAQ:ZIOP

ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of immuno-oncology platforms that leverage cell- and gene-based therapies to treat patients with cancer. Its pipeline includes Sleeping Beauty TCR-T Targeting neoantigens; Ad-RTS-hlL-12 + veledimex; and Sleeping Beauty CAR-T. The company was founded on September 9, 2003 and is headquartered in Boston, MA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time